Xinhé Bio Ranks Among Top 10 Most Promising Vaccine Companies on 2025 China Biopharma Innovation Value List with AI-Powered mRNA Cancer Vaccines
NeoCura
RNA Innovative Drug Developer
Recently, at the 2025 InnoMatch Global Technology Transfer Conference,Huayi List·2025 China Biomedical Science and Technology Innovation Value ListOfficially announced.NeoCura, which focuses on AI + RNA innovative drug research and development, has successfully made it to the list of "Top 10 Most Growth-Oriented Vaccine Enterprises" thanks to its technological breakthroughs and forward-looking layout in the field of mRNA tumor vaccines.
「Huayi List · China Biomedical Science and Technology Innovation Value List」After four years of沉淀, it has become a 风向标 for guiding the innovation value of China's biopharmaceutical industry with its authority and credibility. The selection of this list is mainly based on six core elements: strategy, product, team, competition, business, and value, adopting a scientific and quantitative enterprise evaluation model. It aims to objectively and fairly discover the innovative forces in the industry and provide authoritative value references for the industry and capital.
In 2025, the biopharmaceutical industry enters a critical period of comprehensive recovery and transformation and upgrading, with policies, technologies, and markets working together to continuously deliver innovative achievements.
As a leading enterprise in the field of AI + RNA innovative drug research and development in China, NeoCura has independently developed the NeoCura AI ALPINE tumor neoantigen prediction system. By integrating multi-omics data with artificial intelligence algorithms, it significantly enhances the specificity and sensitivity of neoantigen screening. Compared with the public data from the international neoantigen consortium TESLA dataset, the prediction accuracy rate has increased by more than 30%, reaching a globally leading level, providing solid technical support for the research and development of mRNA tumor neoantigen vaccines.
On this basis, NeoCura has overcome the key technical bottleneck in the personalized customization of mRNA vaccines. Its self-developed mRNA personalized tumor neoantigen vaccine XH001 has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration to conduct clinical research, providing a new option for adjuvant treatment in patients with high-risk solid tumors after radical surgery.
Preclinical studies show that the vaccine successfully activates the immune system, induces specific T cells, and precisely kills tumor cells. This achievement further demonstrates NeoCura's strong capabilities in mRNA tumor vaccine research and development, laying a foundation for subsequent pipeline development and clinical applications.
Looking ahead, NeoCura will continue to fulfill its mission of "Better medicine for a better life," accelerate technological iteration and product innovation, deepen the application of AI technology throughout the entire process of innovative drug development, effectively improve R&D efficiency, and provide more safe, effective, and accessible treatment options for patients worldwide, truly transforming scientific research achievements into "powerful tools" that save lives.
More content, click "Read Original" below.
